- Home
- PTGX
as 07-14-2025 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 3.3B | IPO Year: | 2016 |
| Target Price: | $67.11 | AVG Volume (30 days): | 925.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.86 | EPS Growth: | -68.10 |
| 52 Week Low/High: | $32.50 - $60.60 | Next Earning Date: | 08-05-2025 |
| Revenue: | $207,801,000 | Revenue Growth: | -34.02% |
| Revenue Growth (this year): | -80.91% | Revenue Growth (next year): | 53.09% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jun 9 '25 | Sell | $56.27 | 20,000 | $1,125,400.00 | 83,892 | |
| Ali Asif | PTGX | Chief Financial Officer | Apr 22 '25 | Sell | $46.00 | 1,756 | $80,776.00 | 61,065 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
18 days ago
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Argus Research
20 days ago
PTGX: Lowering target price to $56.00
Insider Monkey
20 days ago
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Insider Monkey
24 days ago
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
MT Newswires
a month ago
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target
Argus Research
a month ago
PTGX: Rating decreased to a HOLD
The Wall Street Journal
a month ago
For Patients With Rare Blood Cancer, New Drug Offers Relief
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks In The US Market
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.